Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis

详细信息    查看全文

• 作者：Yasunori Kogure ; Akihide Yoshimi ; Koki Ueda ; Yasuhito Nannya…
• 关键词：Salvage chemotherapy ; Peripheral T cell lymphoma ; Angioimmunoblastic T cell lymphoma ; Bone marrow involvement ; Retrospective study
• 刊名：Annals of Hematology
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：94
• 期：6
• 页码：989-994
• 全文大小：274 KB
• 参考文献：1.Vose J, Armitage J, Weisenburger D, Project IT-CL (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124-130View Article PubMed
  2.Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM (2004) Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15(10):1467-475View Article PubMed
  3.Horwitz S, Moskowitz C, Kewalramani T, Hamlin P, Straus D, O'Connor O, Noy A, Portlock C, Nimer S, Palomba ML, Zelenetz A (2005) Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat. Blood 106(11):abstract 2679
  4.Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F (1994) ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12(6):1169-176PubMed
  5.Ueda K, Nannya Y, Asai T, Yamamoto G, Hangaishi A, Takahashi T, Imai T, Kurokawa M (2010) Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma. J Chemother 22(1):54-7View Article PubMed
  6.(1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329 (14):987-94
  7.Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting. J Clin Oncol 7(11):1630-636PubMed
  8.Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244PubMed
  9.Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748-756PubMed
  10.Uni M, Yoshimi A, Nakamura F, Takazawa Y, Fukayama M, Kurokawa M (2013) Successful allogeneic stem cell transplantation for Lennert lymphoma. Ann Hematol 92(6):859-60View Article PubMed
  11.Non-Hodgkin's Lymphomas Guideline (Version 2.2014) National Comprehensive Cancer Network. http://?www.?nccn.?org/?professionals/?physician_?gls/?pdf/?nhl.?pdf . Accessed 30 June 2014
  12.Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH (2003) Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 14(Suppl 1):i5–i10View Article PubMed
  13.Park SH, Kim S, Ko OB, Koo JE, Lee D, Jeong YP, Huh J, Kim SB, Kim SW, Lee JL, Suh C (2006) ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience. Korean J Intern Med 21(3):159-64View Article PubMed Central PubMed
  14.Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21(4):860-63View Article PubMed
  15.Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A, Matutes E (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92(2):271-72View Article PubMed
  16.O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182-189View Article PubMed Central PubMed
  17.Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30(6):631-36View Article PubMed
  18.Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P,
• 作者单位：Yasunori Kogure (1)
  Akihide Yoshimi (1)
  Koki Ueda (1)
  Yasuhito Nannya (1)
  Motoshi Ichikawa (1)
  Fumihiko Nakamura (1)
  Mineo Kurokawa (1)
  
  1. Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584

文摘

Peripheral T cell lymphomas account for approximately 10?% of all the non-Hodgkin lymphomas and are characterized by an aggressive clinical course and poor treatment outcome. In contrast to the improvement in the treatment of B cell lymphomas, there is no established standard chemotherapy regimen for relapsed/refractory T cell lymphomas. Our institute introduced modified ESHAP (mESHAP) regimen to reduce renal toxicity of standard ESHAP therapy, in which cisplatin was switched to carboplatin. We retrospectively analyzed the efficacy of mESHAP against relapsed/refractory T cell lymphomas. Twenty-two patients with relapsed/refractory T cell lymphomas were treated with mESHAP regimen at the University of Tokyo Hospital between January 2001 and December 2012. The median age was 59?years (range, 36-7). The diagnosis comprised peripheral T cell lymphoma, not otherwise specified (n--0), angioimmunoblastic T cell lymphoma (AITL; n--), mycosis fungoides (n--), and anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (n--). The median follow-up period was 9.5?months (range, 2.5-2.3). Complete remission (CR) was achieved in four patients (18?%) and partial remission (PR) in three patients (14?%). The median overall survival (OS) and progression-free survival (PFS) were 11.0 and 2.5?months, respectively. Leukopenia was the most frequent side effect and renal impairment was rare. According to a multivariate analysis, better OS and PFS were recorded in patients without bone marrow invasion (OS, hazard ratio (HR) 0.13, p--.0079; PFS, HR 0.13, p--.0044) or those with AITL (OS, HR 0.21, p--.021; PFS, HR 0.15, p--.0043). Although overall outcomes of mESHAP for relapsed/refractory T cell lymphomas were not excellent, this regimen remains one of the possible candidates for those with AITL histology or without bone marrow invasion